Brasilia Parkinson Cohort: assessing clinical, neuropsychological and imaging predictors of cognitive decline in Parkinson's disease
- Published
- Accepted
- Subject Areas
- Neuroscience, Cognitive Disorders, Neurology, Radiology and Medical Imaging
- Keywords
- non-motor symptoms, cognitive dysfunction, neuroimaging, cohort study, Parkinson disease, dementia, mild cognitive impairment, apathy, biomarker
- Copyright
- © 2019 de Paula Brandão et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
- Cite this article
- 2019. Brasilia Parkinson Cohort: assessing clinical, neuropsychological and imaging predictors of cognitive decline in Parkinson's disease. PeerJ Preprints 7:e27639v1 https://doi.org/10.7287/peerj.preprints.27639v1
Abstract
The following study protocol describes the rationale and methods of a cohort with a nested case-control study, which aims to identify risk factors and predictors of cognitive dysfunction in Parkinson's disease (PD). It is a study that will follow PD every 18 months with a comprehensive neuropsychological, clinical (motor and non-motor symptoms) and imaging (Magnetic Resonance Imaging) data collection. The criteria for diagnosing mild cognitive impairment (MCI) and dementia will respect the parameters previously published by the International Working Group on Mild Cognitive Impairment, and compared with those recommended by the Fifth edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association (DSM-5) and the International Parkinson's and Movement Disorders Society (MDS) criteria. We will also evaluate the neural substrate and underpinnings of PD non-motor symptoms, using advanced neuroimaging techniques, such as diffusion tensor imaging (DTI) and gray matter and white matter volumetric measurements.
Author Comment
Study protocol as submitted for ethical review, in preparation for a peer-reviewed journal.
Supplemental Information
Figure 1 – Brasilia Parkinson Cohort study design
The figure describes the enrollment process, along with outcome measures, clinical data, neuroimaging and neuropsychological assessments. MRI= Magnetic resonance imaging; CANTAB = Cambridge Automated Neuropsychological Assessment Battery; MoCA= Montreal Cognitive Assessment; PD-CRS=Parkinson’s disease- Cognitive Rating Scale; TMT-A and -B: Trail Making Test Parts A and B; SDMT=Symbol Digit Modalities Test; WAIS-III=Wechsler’s Adult Intelligence Scale 3rdedition; NMSS=Non-motor symptoms scale; BDI= Beck Depression inventory; BSI= Beck Suicide Ideation Scale; HADS= Hospital Anxiety and Depression Scale; PDSS-BR=Parkinson’s disease Sleep Scale, Brazilian version; RBDSQ= Rapid eye movement sleep Behavior Disorder Screening Questionnaire; SAS= Starkstein Apathy Scale; QUIP-CS= Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease- Current Short; QUIP-RS= Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease- Rating Scale; PD-CFRS= Parkinson’s disease-Cognitive Functional Rating Scale; MDS-UPDRS=International Parkinson and Movement Disorders-Unified Parkinson’s disease Rating Scale; DTI=Diffusion tensor imaging; TFE=turbo field echo; FLAIR=Fluid attenuated inversion recovery; PDQ-8=Parkinson’s disease Questionnaire – Short version (8-item);